Qiagen Q1 Revenues Fall 23 Percent but Exceed Outlook, Analyst Estimates
Qiagen also reported double-digit growth at constant exchange rates in its non-COVID product groups.
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Qiagen Gets CE Mark for QuantiFERON-TB Gold Plus Under New EU Framework
The test is one of more than 180 products Qiagen plans to transition to meet the more stringent regulatory bar for in vitro diagnostics.
Qiagen said its non-COVID portfolio grew 8 percent, or 15 percent at constant exchange rates, in Q4, offsetting a decline in COVID-related sales.
Qiagen, Helix Partner for Hereditary Disease CDx Development
The partnership will leverage Helix's whole-exome sequencing platform and incorporate Qiagen's biopharma relationships, NGS capabilities, and global regulatory expertise.